Skip to Content

Uroxatral (alfuzosin) Disease Interactions

There are 3 disease interactions with Uroxatral (alfuzosin):


Alfuzosin (Includes Uroxatral) ↔ hepatic impairment

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment (Child Pugh B and C). The pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment and caution should be exercised if it is administered to such patients.


Alfuzosin (Includes Uroxatral) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Caution should be exercised when alfuzosin is administered in patients with severe renal impairment as safety data is limited on these patients (CrCl < 30 mL/min).


Antiadrenergic agents (Includes Uroxatral) ↔ cataracts

Moderate Potential Hazard, Moderate plausibility. Applies to: Cataracts

Intraoperative Floppy Iris Syndrome has been observed during cataract surgery in some patients on or previously treated with antiadrenergic agents. If a patient is undergoing cataract surgery, the ophthalmologist should be prepared for possible modifications of the surgical technique (iris hooks, iris dilator rings). There does not appear to be a benefit in stopping antiadrenergic agents therapy prior to the cataracts surgery.

Uroxatral (alfuzosin) drug interactions

There are 806 drug interactions with Uroxatral (alfuzosin)

Uroxatral (alfuzosin) alcohol/food interactions

There are 2 alcohol/food interactions with Uroxatral (alfuzosin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.